每经AI快讯，港股汽车股今日普涨。截至发稿，吉利汽车(00175.HK)涨5.61%，报16.01港元；零跑汽车 (09863.HK)涨4.63%，报40.24港元；小鹏汽车-W(09868.HK)涨3.93%，报66.15港元；长城汽车 (02333.HK)涨2.96%，报12.87港元。 ...

值得一提的是，3月5日，比亚迪（002594）举办第二代刀片电池暨闪充技术发布会，会上公司重点发布 新一代刀片电池，其在闪充速度、能量密度、安全和寿命上均实现升级，主打"5分钟充好、9分钟充 饱、零下30°C只多3分钟"。申万宏源指，小鹏比亚迪新技术发布，投资进入事件催化密集期。光大证 券表示，3-4月开始，多家车企多款重磅新车即将密集上市；短期聚焦成本上涨的财报业绩表现。 汽车股今日普涨，截至发稿，吉利汽车(00175)涨5.61%，报16.01港元；零跑汽车(09863)涨4.63%，报 40.24港元；小鹏汽车-W(09868)涨3.93%，报66.15港元；长城汽车（601633）(02333)涨2.96%，报12.87 港元。 消息面上，今年的政府工作报告提出实施消费品以旧换新、推动人工智能商业化规模化应用、深入整 治"内卷式"竞争等。山西证券指出，在"反内卷"政策指导的大背景下，2026年汽车行业有望加速走向以 科技与创新为代表的高质量发展，代替之前的价格竞争。智能化与轻量化将有望成为汽车行业的两 大"增量"。 ...

该行认为，ASMPT很可能转型为一家销售更多热压焊接设备的纯先进封装设备公司。分析显示，热压 焊接约占2025年半导体解决方案销售的25%，但预期到2028年将占比超过50%。 美银证券发布研报称，重申对ASMPT(00522)的"买入"评级，并在上调2026至2027年每股盈测后，将目 标价由150港元上调至160港元。ASMPT管理层在2025年第四季业绩电话会议上提供乐观的指引，包括 热压焊接(TCB)设备的增长前景，以及基于在逻辑及HBM领域的稳固地位，目标取得35%至40%的市场 份额。旨在更聚焦先进封装或热压焊接的重组计划亦获充分讨论，但未公布具体时间表。 ...

Core Viewpoint - Goldman Sachs reported that JD Logistics achieved a revenue of 63.5 billion yuan in Q4 last year, representing a year-on-year growth of 22%, slightly exceeding the bank's forecast of 21% [1] Group 1: Financial Performance - The internal comprehensive supply chain revenue reached 26.7 billion yuan, with a year-on-year growth of 68%, outperforming the bank's expectation of 10% [1] - Adjusted net profit was 2.4 billion yuan, surpassing the bank's forecast by 5% [1] Group 2: Investment Rating - Goldman Sachs has assigned a "Buy" rating to JD Logistics, with a 12-month target price of 17.4 HKD based on a sum-of-the-parts valuation method [1] - The positive outlook is supported by JD Logistics' leading position in the Chinese supply chain industry, proven business model, and technological expertise [1]

3月6日，港股终于迎来强劲反弹，互联网龙头集体上攻，截至发稿，阿里巴巴-W、小米集团-W、美团- W、腾讯控股均涨超3%，港股AI核心资产——港股互联网ETF（513770）自低位掉头向上，场内价格 现涨2.49%，强势收复5日线。 看好港股科技但又希望降低波动？也可以关注全市场首只——香港大盘30ETF（520560），自带"科技 +红利"哑铃策略，重仓股既有阿里巴巴、腾讯控股等高弹性科技股，又囊括了建设银行、中国平安等 稳健高股息，是港股长期配置的理想底仓工具。 提醒：近期市场波动可能较大，短期涨跌幅不预示未来表现。请投资者务必根据自身的资金状况和风险 承受能力理性投资，高度注意仓位和风险管理。 数据来源：沪深交易所等。中证港股通互联网指数近5个完整年度的涨跌幅分别为： 2021 年，-36.61%；2022年，-23.01%；2023年，-24.74%；2024年，23.04%；2025年，27.02%。指数成份股 构成根据该指数编制规则适时调整，其回测历史业绩不预示指数未来表现。 机构观点来源：广发证券20260209《春节前后港股或同步A股出现阶段性上涨的情形》。 ETF费用相关说明：投资者在申购或 ...

Core Viewpoint - The exclusive global licensing agreement between China National Pharmaceutical Group (China Biologic) and Sanofi for the innovative drug Rovaxtinib marks a significant milestone in the recognition of Chinese pharmaceutical companies by multinational corporations (MNCs) [4][14]. Group 1: Transaction Overview - The agreement grants Sanofi exclusive rights to develop, manufacture, and commercialize Rovaxtinib globally, with potential total payments reaching up to $1.53 billion [1]. - This transaction is notable as it is the first innovative drug licensing project between a Chinese pharmaceutical company and an MNC in recent years, highlighting the growing trust and collaboration in the industry [4][14]. Group 2: Product Significance - Rovaxtinib is the world's first JAK/ROCK dual-target small molecule inhibitor, demonstrating significant clinical value in treating myelofibrosis and chronic graft-versus-host disease (cGVHD) [8][10]. - The drug has shown promising clinical data, with a 59.1% improvement in graft-versus-host symptoms and an 86.4% overall response rate in clinical trials [13]. Group 3: Strategic Implications - For China Biologic, the transaction provides immediate financial benefits and long-term revenue stability through milestone payments and sales sharing [14]. - Sanofi can leverage its global resources to maximize Rovaxtinib's market potential, aligning with its existing pipeline in hematological diseases [14]. Group 4: Industry Trends - The deal signifies a shift in the industry, where the full-chain R&D capabilities of Chinese pharmaceutical companies are increasingly recognized by MNCs, enhancing mutual trust [4][15]. - China Biologic's successful collaboration with Sanofi reflects its robust innovation pipeline and growing international presence, paving the way for future global partnerships [15][17].

Core Viewpoint - The Hong Kong stock market has experienced a strong rebound, particularly in the internet sector, with major companies like Alibaba, Xiaomi, Meituan, and Tencent all seeing gains of over 3% [1][8]. Market Performance - The Hong Kong internet sector's current price-to-earnings ratio (PE) is 20.74, which is significantly lower than the NASDAQ 100's 32.85 and the ChiNext Index's 41.52, indicating a strong valuation margin [3][10]. - The Hong Kong internet ETF (513770) has risen by 2.49%, recovering above the 5-day moving average [1][8]. Financial Results - Recent earnings reports from internet companies have alleviated concerns about increasing losses, confirming the positive impact of AI as a "second growth curve" [3][10]. - Bilibili is projected to achieve its first annual profit in 2025, with an adjusted net profit of 2.59 billion yuan, while JD Health expects revenue and net profit growth of 26.3% and 29.16% respectively in 2025 [3][10]. Investment Outlook - Analysts suggest that the technology sector remains a long-term investment focus for Hong Kong stocks, with the recent market correction creating buying opportunities [3][10]. - The rise of AI capabilities in China is expected to bolster market confidence, with attention on the progress of large model applications and overseas liquidity trends [3][10]. ETF and Fund Information - The Hong Kong internet ETF (513770) and its linked funds (Class A 017125; Class C 017126) passively track the CSI Hong Kong Internet Index, with top holdings including Alibaba, Tencent, Xiaomi, Kuaishou, and Bilibili, collectively accounting for over 76% of the fund [3][11]. - For investors looking to reduce volatility, the Hong Kong Large Cap 30 ETF (520560) offers a "technology + dividend" strategy, featuring both high-growth tech stocks and stable dividend-paying companies [5][11].

Group 1 - The Hang Seng Index opened up by 0.15% [1] - The Hang Seng Tech Index increased by 0.47% [1] - JD Logistics rose by over 6% [1] - JD Health and Trip.com Group both increased by over 3% [1] - NetEase, JD Group, and Xiaomi Group showed significant gains [1]

2026年3月3日，泰格医药集团旗下方达控股宣布已正式完成对观合医药的收购。此次收购将进一步完善 方达在全球中心实验室领域的布局，强化其在中国及亚太地区的综合服务能力。 观合医药是中国领先的临床研究实验室服务提供商，累计支持超过1,500项临床试验，覆盖多个治疗领 域。公司长期按照GCP规范开展运营，实验室通过CAP认证，同时获得NGSP Level 1实验室资质，并具 备放射性乙类工作场所资质。凭借成熟稳健的运营体系，观合医药持续为国内外制药企业和生物技术公 司提供符合国际监管要求、可支持审计的高质量实验室检测服务。在支持监管核查及新药注册申报方 面，公司积累了丰富经验，已助力50个新药成功获批上市。 收购完成后，方达控股将在中国进一步拓展中心实验室网络布局，提升对国内临床研究及多区域临床试 验（MRCT）的综合支持能力。通过整合观合医药在中心实验室领域的成熟运营经验，以及方达覆盖生 物分析、DMPK、安全性评价、CMC和临床研究支持等在内的一体化服务平台，方达将进一步提升端 到端研发服务能力，为全球制药企业、生物技术公司及科研机构提供更加高效、合规、协同的综合解决 方案。 方达控股相关负责人表示： "观合 ...

本文源自：市场资讯 作者：情报员 国家知识产权局信息显示，中国铁塔股份有限公司取得一项名为"一种数据类别确定方法、产品及装 置"的专利，授权公告号CN116049767B，申请日期为2023年2月。 天眼查资料显示，中国铁塔股份有限公司，成立于2014年，位于北京市，是一家以从事土木工程建筑业 为主的企业。企业注册资本1760084.7102万人民币。通过天眼查大数据分析，中国铁塔股份有限公司共 对外投资了4家企业，参与招投标项目99473次，财产线索方面有商标信息185条，专利信息1156条，此 外企业还拥有行政许可77个。 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 ...